Sanofi India Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
SANOFI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sanofi India reported Q1 FY26 revenue from operations of ₹4,063 million, down 12.3% from ₹4,635 million in the same quarter last year. Profit after tax (continuing operations) for the quarter was ₹695 million, slightly up from ₹682 million, translating to basic EPS of ₹30.18 versus ₹29.62. For the half-year ended June 30, 2025, revenue from continuing operations fell 3.3% to ₹9,422 million, while profit from continuing operations rose to ₹1,890 million from ₹1,402 million. The company disclosed a new promotion and distribution agreement with Emcure Pharmaceuticals for its Oral Anti-diabetic (OAD) business. The Board also noted the retirement of Whole-time Director Ms. Renee Amonkar and the appointment of Mr. Mahadev Gawade in her place, effective August 11, 2025.
The double-digit quarterly revenue decline is a notable concern, though PAT held steady, suggesting cost discipline. Investors should watch the new Emcure OAD partnership for future revenue traction, while director transition at the Goa site is a routine succession.